New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations
Open Access
Abstract
Pharmacokinetic (PK) studies improve the design of dosing regimens in preclinical and clinical settings. In complex diseases like cancer, single-agent approaches are often insufficient for an effective treatment, and drug combination therapies can be implemented. In this work, in silico PK models were developed based on in vitro assays results, with the goal of predicting the in vivo performance of drug combinations in the context of cancer therapy. Combinations of reference drugs for cancer treatment, gemcitabine and 5-fluorouracil (5-FU), and repurposed drugs itraconazole, verapamil or tacrine, were evaluated in vitro. Then, two-compartment PK models were developed based on the previous in vitro studies and on the PK profile reported in the literature for human patients. Considering the quantification parameter area under the dose-response-time curve (AUCeffect) for the combinations effect, itraconazole was the most effective in combination with either reference anticancer drugs. In addition, cell growth inhibition was itraconazole-dose dependent and an increase in effect was predicted if itraconazole administration was continued (24-h dosing interval). This work demonstrates that in silico methods and AUCeffect are powerful tools to study relationships between tissue drug concentration and the percentage of cell growth inhibition over time.Keywords
This publication has 39 references indexed in Scilit:
- PBPK modeling and simulation in drug research and developmentActa Pharmaceutica Sinica B, 2016
- Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cellsInternational Journal of Oncology, 2016
- Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro–in-silico–in-vivo approachJournal of Pharmacy and Pharmacology, 2015
- Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened AntagonistsCancer Cell, 2013
- Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistanceBiomaterials, 2011
- Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer GrowthCancer Cell, 2010
- An Overview of Drug Combination Analysis with IsobologramsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous doseInt. Journal of Clinical Pharmacology and Therapeutics, 2000
- From genotype to phenotype: computer-based modeling of gene expression with STELLA II.1993
- CLINICAL PHARMACOKINETICS OF 5-FLUOROURACIL AND ITS METABOLITES IN PLASMA, URINE, AND BILE1987